Collaborate With A Trusted Partner To Bring Your Rare Disease Therapy To Clinic


Though rare diseases have long represented a major unmet medical need, a new range of therapeutic possibilities is offering hope to the 400 million people affected by rare diseases worldwide. As a growing number of therapies enter clinical trials, drug developers must be strategic about how they approach manufacturing scaleup. To help ensure success, many developers opt to partner with a CDMO that has previous experience with development, manufacturing, and regulatory engagement.

In a webinar hosted by FUJIFILM Diosynth Biotechnologies (FDB), FDB’s Director of Viral Gene Therapy Operations, Dr. Joanna Norman, and Director of Strategic Technical Marketing, Dr. Rebecca Abram, discuss how the gene therapy landscape has rapidly evolved to offer treatment possibilities for rare disease patients and how a knowledgeable CDMO can guide you through each phase of development. Following the webinar, Norman and Abram answered audience questions about the markers of a high caliber CDMO partner. Interested? Download the full article to read more.

access the Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma

FUJIFILM Diosynth Biotechnologies